Trial · NCT05270525
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
NCT05270525, Phase 2, Active not recruiting, Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207). Trials, record NCT05270525. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05270525
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
- NCT number
- NCT05270525
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, actual
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD
- Interventions
- Ensifentrine, Placebo, LABA/LAMA
- First posted
- 2022-03-08
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes33
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Absolute Change From Baseline in Sputum Neutrophil Cell Numbers | Baseline and 8 Weeks | The Absolute change from baseline in sputum neutrophil cell numbers will be reported. |
| Secondary | Absolute Change in Cell Numbers From Baseline in Sputum Cell Counts | Baseline and 8 Weeks | Absolute change in cell numbers from baseline in sputum cell counts (eosinophils, basophils, macrophages, lymphocytes, total cells) will be reported. |
| Secondary | Percent Change From Baseline in Sputum Cell Counts | Baseline and 8 Weeks | Percent change from baseline in sputum cell counts (neutrophils, eosinophils, basophils, macrophages, lymphocytes, and total cells) will be reported. |
| Secondary | Percent Change From Baseline in Cytokines | Baseline and 8 Weeks | Percent Change From Baseline in Cytokines will be reported. |
| Secondary | Percent Change From Baseline in Proteases | Baseline and 8 Weeks | Percent Change From Baseline in Proteases will be reported. |
| Secondary | Percent Change From Baseline in Markers of Inflammation | Baseline and 8 Weeks | Percent Change From Baseline in Markers of Inflammation will be reported. |
| Secondary | Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in FEV1 at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in FEV1 at 8 Weeks | Baseline and 8 Weeks | Change from baseline in FEV1 at 8 weeks during the treatment period (postdose) will be reported. |
| Secondary | Change From Baseline in Forced Vital Capacity (FVC) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in FVC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in FVC at 8 Weeks | Baseline and 8 Weeks | Change from baseline in FVC at 8 weeks during the treatment period (postdose) will be reported. |
1 to 10 of 33Source ClinicalTrials.gov
See all 33 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05270525
GET https://conductscience.org/api/trials/v1/NCT05270525/registered?page=2